摘要
糖尿病性黄斑水肿(diabetic macular edema,DME)的临床一线治疗方法为玻璃体注射抗血管内皮生长因子药物。治疗并延长方案(treat and extend,T&E)是一种主动治疗方案,患者接受治疗至病灶稳定,在随访期间可根据疾病是否稳定来延长或缩短治疗间隔,该方案正逐步应用于DME。与现有常用的治疗方案相比,T&E方案降低每月固定方案注射次数及过度治疗的风险,同时避免每2个月方案治疗不足的可能;与按需治疗方案相比,可依据最佳矫正视力或中央视网膜厚度来调整随访间隔,通过规律地治疗提高视力并改善解剖结构。但目前T&E方案设计尚无统一标准,尚需更多的临床研究进一步规范。
The first-line clinical treatment for diabetic macular edema(DME)is intravitreal injection of anti-vascular endothelial growth factor(anti-VEGF).Treat and extend(T&E)is an active treatment regimen in which patients are treated until the lesion is stable and the interval of treatment can be extended or shortened during the follow-up period depending on whether the disease is stable.This regimen is being progressively used in the treatment of patients with DME.Compared with commonly used treatment regimens,the T&E regimen reduces the risk of fewer fixed injections per month and overtreatment while avoiding the possibility of undertreatment every two months.Follow-up intervals can be adjusted according to best-corrected visual acuity(BCVA)or central retinal thickness(CRT),and regular treatment can improve vision and anatomy as compared to on-demand treatment regimens.However,there is no unified standard for the design of T&E protocol in the current study,and more clinical studies are needed to further standardize it.
作者
尹立东
蒋博
张中宇
孙大卫
Yin Lidong;Jiang Bo;Zhang Zhongyu;Sun Dawei(Department of Ophthalmology,the Second Affiliated Hospital of Harbin Medical University,Harbin 150086,China)
出处
《国际眼科纵览》
2021年第6期477-482,共6页
International Review of Ophthalmology
